Overview

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Status:
RECRUITING

Trial end date:
2032-12-31

Target enrollment:

Participant gender:

Summary

To find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the body, respectively). To further test the dose found in Part A to see if it can help to control liposarcoma growth.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Cyclophosphamide